[{"id":"3e01dea9-3971-4487-84c5-6452884a557d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00972478","created_at":"2021-01-18T03:47:26.597Z","updated_at":"2025-02-25T16:36:04.200Z","phase":"Phase 1/2","brief_title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT00972478","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 11/15/2010","start_date":" 11/15/2010","primary_txt":" Primary completion: 12/30/2015","primary_completion_date":" 12/30/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"facf7f83-63bf-49f3-a6fb-2b75c0782dba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848687","created_at":"2023-05-08T15:04:02.177Z","updated_at":"2025-02-25T17:26:10.730Z","phase":"Phase 1/2","brief_title":"TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II","source_id_and_acronym":"NCT05848687","lead_sponsor":"Tanja Andrea Gruber","biomarkers":" KMT2A","pipe":" | ","alterations":" CD19 positive","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • Komzifti (ziftomenib) • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2025-01-31"},{"id":"a6924d5b-de24-40e2-b106-96da6cb8e6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06693284","created_at":"2025-02-25T15:37:46.378Z","updated_at":"2025-02-25T15:37:46.378Z","phase":"Phase 1","brief_title":"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","source_id_and_acronym":"NCT06693284","lead_sponsor":"University of Minnesota","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-01-14"},{"id":"ae7646c4-bdd2-4ca0-bea5-d4ff44e6ab1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02638090","created_at":"2021-01-17T17:24:57.690Z","updated_at":"2025-02-25T16:15:36.177Z","phase":"Phase 1/2","brief_title":"Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02638090","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • ROS1","pipe":"","alterations":" ","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/22/2016","start_date":" 03/22/2016","primary_txt":" Primary completion: 01/21/2024","primary_completion_date":" 01/21/2024","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2024-11-27"},{"id":"9d6eb8a2-227e-4af0-a797-a3385d961585","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742245","created_at":"2021-01-18T18:19:48.582Z","updated_at":"2025-02-25T15:08:07.270Z","phase":"Phase 1","brief_title":"Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer","source_id_and_acronym":"NCT03742245","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-11-22"},{"id":"f270357c-b837-458a-950f-910b0ee31575","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587352","created_at":"2023-11-26T19:51:41.019Z","updated_at":"2024-07-02T16:35:00.381Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01587352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • BAP1 • GNA11","pipe":"","alterations":" ","tags":["GNAQ • BAP1 • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/29/2012","start_date":" 05/29/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"25179c5b-c443-4dc5-8695-a99257e723d2","acronym":"PEDS-PLAN","url":"https://clinicaltrials.gov/study/NCT02559778","created_at":"2021-01-18T12:23:35.740Z","updated_at":"2024-07-02T16:35:10.996Z","phase":"Phase 2","brief_title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","source_id_and_acronym":"NCT02559778 - PEDS-PLAN","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-04-08"},{"id":"1fc39e25-1922-47e5-b3b9-847ab787c19c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03842696","created_at":"2021-01-18T18:58:09.458Z","updated_at":"2025-02-25T16:25:22.587Z","phase":"Phase 1/2","brief_title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","source_id_and_acronym":"NCT03842696","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zolinza (vorinostat) • cyclosporine"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 02/04/2020","start_date":" 02/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-02"},{"id":"6d194b66-a36a-4049-9be1-f272a6096889","acronym":"","url":"https://clinicaltrials.gov/study/NCT03117751","created_at":"2021-01-18T15:21:39.440Z","updated_at":"2024-07-02T16:35:16.300Z","phase":"Phase 2/3","brief_title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT03117751","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BCL2 • CEP72","pipe":"","alterations":" ","tags":["BCL2 • CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Erwinase (erwinia asparaginase) • Purixan (mercaptopurine oral suspension) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-03-05"},{"id":"882f5b6b-c9b5-4e56-a035-53a70ca3ee86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03259503","created_at":"2021-01-18T16:06:12.176Z","updated_at":"2024-07-02T16:35:16.440Z","phase":"Phase 1","brief_title":"Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant","source_id_and_acronym":"NCT03259503","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • gemcitabine • Rituxan (rituximab) • Zolinza (vorinostat) • melphalan • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-03-05"},{"id":"dc1b4241-b63f-4ce1-9ee2-12f37ef53e52","acronym":"","url":"https://clinicaltrials.gov/study/NCT00616967","created_at":"2021-01-18T02:17:32.968Z","updated_at":"2024-07-02T16:35:20.452Z","phase":"Phase 2","brief_title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","source_id_and_acronym":"NCT00616967","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-07"},{"id":"93f8fa02-65f9-4720-b1b6-08c127952558","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756660","created_at":"2023-03-08T17:01:27.729Z","updated_at":"2024-07-02T16:35:23.123Z","phase":"Phase 1","brief_title":"Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy","source_id_and_acronym":"NCT05756660","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-01-18"},{"id":"4ce913fc-70e5-4eaa-bf17-ac87c5e8708f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04220008","created_at":"2021-01-18T20:32:29.778Z","updated_at":"2024-07-02T16:35:23.576Z","phase":"Phase 2","brief_title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04220008","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • cyclophosphamide • Zolinza (vorinostat) • clofarabine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 10/29/2021","primary_completion_date":" 10/29/2021","study_txt":" Completion: 10/29/2021","study_completion_date":" 10/29/2021","last_update_posted":"2024-01-12"},{"id":"01748141-8c11-4ec6-b115-e25190e90e45","acronym":"","url":"https://clinicaltrials.gov/study/NCT02316340","created_at":"2021-01-18T10:58:33.824Z","updated_at":"2024-07-02T16:35:24.469Z","phase":"Phase 2","brief_title":"Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer","source_id_and_acronym":"NCT02316340","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Zolinza (vorinostat) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 03/07/2018","primary_completion_date":" 03/07/2018","study_txt":" Completion: 04/16/2018","study_completion_date":" 04/16/2018","last_update_posted":"2024-01-05"},{"id":"2ec47635-b74f-44b7-8369-7b60baf401db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01193842","created_at":"2021-01-18T04:46:39.937Z","updated_at":"2024-07-02T16:35:28.434Z","phase":"Phase 1/2","brief_title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","source_id_and_acronym":"NCT01193842","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • CD20 negative","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Zolinza (vorinostat) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/06/2010","start_date":" 10/06/2010","primary_txt":" Primary completion: 11/12/2016","primary_completion_date":" 11/12/2016","study_txt":" Completion: 05/19/2022","study_completion_date":" 05/19/2022","last_update_posted":"2023-11-21"},{"id":"5b063683-e06b-4699-9a29-422d240e8a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT03332667","created_at":"2021-07-05T17:09:29.759Z","updated_at":"2024-07-02T16:35:34.961Z","phase":"Phase 1","brief_title":"MIBG With Dinutuximab +/- Vorinostat","source_id_and_acronym":"NCT03332667","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/12/2018","start_date":" 09/12/2018","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-03"},{"id":"f0bfa210-af4d-4908-8483-ac1408f8c7ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01838187","created_at":"2021-01-18T08:11:06.670Z","updated_at":"2024-07-02T16:35:39.738Z","phase":"","brief_title":"Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma","source_id_and_acronym":"NCT01838187","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-17"},{"id":"d08d28eb-68cd-49ac-a524-9a247cdc79ba","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT03561259","created_at":"2021-01-18T17:31:39.370Z","updated_at":"2024-07-02T16:35:55.348Z","phase":"Phase 2","brief_title":"A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects","source_id_and_acronym":"NCT03561259 - OPTIMUM","lead_sponsor":"Jubilant DraxImage Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-02-16"},{"id":"7f51bdeb-9ca6-4832-abd2-10427a80963f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01023737","created_at":"2021-01-18T04:00:54.593Z","updated_at":"2025-02-25T16:00:13.975Z","phase":"Phase 1","brief_title":"Hydroxychloroquine + Vorinostat in Advanced Solid Tumors","source_id_and_acronym":"NCT01023737","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 12/05/2017","primary_completion_date":" 12/05/2017","study_txt":" Completion: 01/08/2023","study_completion_date":" 01/08/2023","last_update_posted":"2023-02-13"},{"id":"cabf613a-e4de-4886-be34-072602ab5414","acronym":"","url":"https://clinicaltrials.gov/study/NCT02042989","created_at":"2021-01-18T09:23:01.961Z","updated_at":"2025-02-25T14:56:53.642Z","phase":"Phase 1","brief_title":"MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies","source_id_and_acronym":"NCT02042989","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Zolinza (vorinostat)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 06/27/2014","start_date":" 06/27/2014","primary_txt":" Primary completion: 01/22/2020","primary_completion_date":" 01/22/2020","study_txt":" Completion: 01/22/2020","study_completion_date":" 01/22/2020","last_update_posted":"2022-07-11"},{"id":"56bf1de6-4149-4ce1-9e77-9b290066ee12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03263936","created_at":"2021-01-18T16:07:26.214Z","updated_at":"2024-07-02T16:36:08.325Z","phase":"Phase 1","brief_title":"Epigenetic Reprogramming in Relapse/Refractory AML","source_id_and_acronym":"NCT03263936","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" BLM","pipe":"","alterations":" ","tags":["BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • Zolinza (vorinostat) • fludarabine IV • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 07/09/2020","primary_completion_date":" 07/09/2020","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2022-06-24"},{"id":"3bea83cb-bd9d-4252-abbf-b6bb189c85ec","acronym":"N2011-01","url":"https://clinicaltrials.gov/study/NCT02035137","created_at":"2021-01-18T09:20:07.243Z","updated_at":"2024-07-02T16:36:09.187Z","phase":"Phase 2","brief_title":"131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat","source_id_and_acronym":"NCT02035137 - N2011-01","lead_sponsor":"New Approaches to Neuroblastoma Therapy Consortium","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • vincristine • Zolinza (vorinostat) • Azedra (iobenguane I 131)"],"overall_status":"Completed","enrollment":" Enrollment 114","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2022-06-08"},{"id":"685fa439-a80a-49f9-a362-d7119d71565f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574587","created_at":"2021-01-18T02:05:54.103Z","updated_at":"2025-02-25T15:57:27.729Z","phase":"Phase 1/2","brief_title":"Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy","source_id_and_acronym":"NCT00574587","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Zolinza (vorinostat) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/01/2007","start_date":" 12/01/2007","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 05/01/2014","study_completion_date":" 05/01/2014","last_update_posted":"2020-10-14"},{"id":"d87ff365-941a-4ef9-bcfe-08a391e022e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00992446","created_at":"2021-01-18T03:52:37.429Z","updated_at":"2024-07-02T16:36:48.253Z","phase":"Phase 2","brief_title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00992446","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • bortezomib • etoposide IV • Zolinza (vorinostat) • carmustine • melphalan • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 09/02/2010","start_date":" 09/02/2010","primary_txt":" Primary completion: 06/17/2015","primary_completion_date":" 06/17/2015","study_txt":" Completion: 10/29/2019","study_completion_date":" 10/29/2019","last_update_posted":"2020-03-18"}]